Oxford Nanopore Technologies’ MinION Disruptive Threat Assessment
- Author: Miguel Edwards
- Date: May, 2017
- Pages: 38 pages
- Price: $ 2,500
There have been a number of key advancements in sequencing technologies since the first generation Sanger sequencing used in the Human Genome Project completed in 2003. The paradigm shift to massively parallel sequencing dramatically increased the amount of DNA that can be sequenced in a given run and ushered in the era of next-generation sequencing (NGS) or second generation sequencing. Continued improvements in competing chemistries and or sequencing approaches has driven down the cost of sequencing a human genome at 30X coverage to ~$1,000.
Third generation sequencing (3GS) could represent a new paradigm shift in sequencing. 3GS, defined in this report as sequencing of single molecules, has no requirement for the amplification of DNA thus eliminating PCR amplification bias introduced in NGS methodologies. One such technology, Nanopore sequencing commercialized by Oxford Nanopore Technologies, has the potential to drive this paradigm shift. In this report we characterize the potential of Oxford Nanopore’s sequencing platform (MinION) to disrupt established NGS technologies.
We interviewed key opinion leaders and current users of the MinION to understand adoption rationale, satisfaction of performance (e.g., accuracy) and workflow (real-time analysis) criteria, key applications, and usage relative to other NGS platforms. In addition, we analyzed MinION publications from 2014 to present to identify key authors and published papers. We also characterized publications by the following criteria:
- -Geography (e.g., Europe, U.S., Canada, APAC, Rest-of-World)
- -Field-of-Study (e.g., Infectious Disease / Microbiology, Human Genetics, Bioinformatics, Transcriptomics, Oncology, Basic Research)
- -Application (e.g., Methodology Development, De Novo Genome Assembly, Antimicrobial Resistance, Microbial Identification, Haplotype Phasing, Platform Benchmarking, SNV/SV Analysis)